[go: up one dir, main page]

WO2025022188A1 - Cathéter de stimulation intracardiaque transveineuse ayant des dérivations améliorées - Google Patents

Cathéter de stimulation intracardiaque transveineuse ayant des dérivations améliorées Download PDF

Info

Publication number
WO2025022188A1
WO2025022188A1 PCT/IB2024/055376 IB2024055376W WO2025022188A1 WO 2025022188 A1 WO2025022188 A1 WO 2025022188A1 IB 2024055376 W IB2024055376 W IB 2024055376W WO 2025022188 A1 WO2025022188 A1 WO 2025022188A1
Authority
WO
WIPO (PCT)
Prior art keywords
leads
ventricle
sheath
atrium
electrode system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/055376
Other languages
English (en)
Inventor
Eduardo De Marchena
Christian Marin Y Kall
Mark Carlson
Sai Nimmagadda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Swift Sync Inc
Original Assignee
Swift Sync Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/358,961 external-priority patent/US12151099B2/en
Application filed by Swift Sync Inc filed Critical Swift Sync Inc
Publication of WO2025022188A1 publication Critical patent/WO2025022188A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/056—Transvascular endocardial electrode systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362—Heart stimulators
    • A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
    • A61N1/368—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions
    • A61N1/3684—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions for stimulating the heart at multiple sites of the ventricle or the atrium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/02—Details
    • A61N1/04—Electrodes
    • A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/056—Transvascular endocardial electrode systems
    • A61N1/0565—Electrode heads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362—Heart stimulators
    • A61N1/365—Heart stimulators controlled by a physiological parameter, e.g. heart potential
    • A61N1/368—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions
    • A61N1/3684—Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions for stimulating the heart at multiple sites of the ventricle or the atrium
    • A61N1/36842—Multi-site stimulation in the same chamber

Definitions

  • the invention relates generally to medical devices that provide heart pacemaking function, and more particularly to a self-positioning, quick-deployment low profile transvenous electrode system for sequentially pacing both the atrium and ventricle of the heart in the “dual chamber” mode having an atraumatic tip comprising a domed head connected to a cylindrical sidewall, said cylindrical sidewall having a sloped proximal edge connected to a tapered coupling, said tapered coupling forming a smooth transition to an outer diameter of the insulated wire, and methods for deploying the same.
  • AV synchrony is estimated to increase stroke volume by as much as 50% in a normal heart and increase cardiac index by as much as 25% to 30%.
  • pacing is performed using epicardial wires that are lightly sutured to the epicardium before the thorax is closed.
  • these pacing wires are pulled through the skin. Pulling the pacing wires represents a risk of a cardiac tamponade that can lead to death, and can also pose a risk of infection, myocardial damage, ventricular arrhythmias and perforation.
  • Existing temporary pacing catheters are also difficult to position correctly and often add complications including, in the case of balloon positioning, having the catheter move to and block the right ventricle outflow tract and the pulmonary artery.
  • Existing pacing catheter leads can also move (dislodge) either while pacing or at a critical point during a specific procedure like rapid pacing. For this reason, the mobility of the patient (ambulation) is limited when being temporary paced.
  • AV sequential pacing catheter that is easy to insert and position within the chambers of the heart, and which avoids endothelial injury to replace the current available temporary catheters/leads.
  • an insertable atrio-ventricular sequential pacing catheter having an atraumatic tip comprising a domed head connected to a cylindrical sidewall, said cylindrical sidewall having a sloped proximal edge connected to a tapered coupling, said tapered coupling forming a smooth transition to an outer diameter of the insulated wire, that is easy to insert and position on the right chambers of the heart.
  • the atraumatic tip prevents tissue damage to the ventricle wall and atrium, and prevents entanglement with and damage to chordae during deployment, adjustment, and withdrawal.
  • the present disclosure relates to a transvenous intracardiac pacing catheter having improved leads, and particularly to devices, methods, and systems for establishing and maintaining atrio-ventricular (AV) synchrony in a patient by providing an insertable atrio-ventricular sequential pacing catheter system having an inner ventricular sheath disposed within a central axial conduit (lumen) of an atrial sheath.
  • the ventricular sheath houses three (3) ventricle leads, including a distal lead and two ventricular wall leads.
  • the atrial sheath has four (4) perimeter conduits (lumens) and a central axial conduit. The four perimeter conduits (lumens) housing the atrium leads for delivery to the atrium.
  • the lead wires are leads for the atrium, two of the lead wires are for the ventricle, and one of the lead wires forms the distal tip.
  • the atrial lead wires are incorporated into a four+one (4+1 ) lumen extrusion.
  • the ventricular and distal lead wires are incorporated into a three lumen “stoplight” extrusion.
  • the ventricular three lumen “stoplight” extrusion is disposed within a central axial lumen or conduit of the atrial sheath.
  • the assembly fitted into correct position using fixtures.
  • the lead wires are exposed sequentially by withdrawing the sheaths.
  • the lead wires are configured with a shape and materials to reduce endothelial injury, and increase performance.
  • the connector assembly attached the lead wires to plugs for connection to the pulse transmission unit.
  • FIGURE 1 is an illustration of one embodiment of an optimized lead having a shape and constructed of materials to reduce endothelial injury and maximize energy transfer and signal transduction, according to the invention.
  • FIGURE 2 is an illustration of one embodiment of an optimized lead having a shape and constructed of materials to reduce endothelial injury and maximize energy transfer and signal transduction, according to the invention.
  • FIGURE 3 is an illustration of one embodiment of an optimized tip of a lead having a shape and constructed of materials to reduce endothelial injury and maximize energy transfer and signal transduction, according to the invention.
  • FIGURE 4 is an illustration of one embodiment of the deployable intracardiac portion of the device, illustrating the distal lead with rounded capsule tip, the two ventricular leads with rounded capsule tips, the four atrial leads with rounded capsule tips, the retractable ventricular sheath, and the retractable atrial sheath, according to the invention.
  • FIGURE 5 is an illustration of one embodiment of the deployable intracardiac portion of the device in relation to the intravascular portion/distal extrusion, the proximal extrusion and the external terminal housing portion, illustrating the distal lead with rounded capsule tip, the two ventricular leads with rounded capsule tips, the four atrial leads with rounded capsule tips, the retractable ventricular sheath, the retractable atrial sheath, the proximal extrusion with distance markers and a stopper, the conical wire guide, and the external lead terminals, according to the invention.
  • FIGURE 6 is an illustration of one embodiment of the conical wire guide in relation to the proximal extrusion and the intracardiac portion of the device, according to the invention.
  • FIGURE 7 is an illustration of one embodiment of the external lead terminal housing in relation to the proximal extrusion and the intracardiac portion of the device, according to the invention.
  • FIGURE 8 is an illustration of one embodiment of the outer shaft with an extension hub, side-port Tuohy-Borst, female luer, and layered construction of the outer sheath, according to the invention.
  • FIGURE 9 is a cross-sectional illustration of the stoplight extrusion used for the ventricle leads.
  • FIGURE 10 is a cross-sectional illustration of the 4+1 extrusion used for the four atrial leads and the inner ventricular sheath.
  • FIGURE 11 is a cross-sectional illustration of the stoplight extrusion used for the ventricle leads disposed within the 4+1 extrusion used for the four atrial leads.
  • FIGURE 12 is a schematic view of one embodiment of the device, illustrating the atrial leads, the ventricular leads, the retractable sheath, the combined hub and terminal connection, and steerable deployment mechanism, and the external lead terminals, according to the invention.
  • FIGURE 13 is a schematic view another embodiment of the device, illustrating the atrial leads, the ventricular leads, the retractable sheath, the hub, the independent terminal connection, and steerable deployment mechanism, and the external lead terminals, according to the invention.
  • FIGURE 14 is a schematic of the two-inner sheath (dual lumen) embodiment illustrating the outer steerable catheter sheath housing the two inner sheaths, with one inner sheath having the ventricle leads and the other inner sheath having the atrium leads, according to the invention.
  • FIGURE 15 is a schematic of the seven-inner sheath (multi-lumen) embodiment illustrating the outer steerable catheter sheath housing the seven inner sheaths, with each inner sheath its own lead, and providing three (3) ventricle leads and four (4) atrium leads, according to the invention.
  • FIGURE 16 is a schematic of a cross-section of the seven-inner sheath (multi-lumen) embodiment illustrating the outer steerable catheter sheath housing the seven inner sheaths, with each inner sheath its own lead, and providing three (3) ventricle leads and four (4) atrium leads, according to the invention.
  • FIGURE 17 is a schematic view of a cross-section of a human heart, a plurality of electrodes inserted in the ventricle and atrium contacting the walls of the heart chambers and a pacer, according to the invention.
  • FIGURE 18 is a chart of an acute first in human study and is useful to support an embodiment of the present invention. This figure shows an example study of a sample of 10 patients, although not necessarily for any specific indication.
  • FIGURE 19 is an example of a chart of data in an embodiment of the invention from a procedure recording a non-limiting preferred embodiment. This figure shows by subject and lead, the impedance, the threshold, and the current, recorded.
  • FIGURE 20 is an illustration of one embodiment of a device being introduced into the jugular vein of a patient, with removal of the guidewire, and introduction of the transvenous dual-chamber sequential pacing device into the steerable catheter sheath, according to the invention.
  • FIGURE 21 is an illustration of one embodiment of the transvenous dual-chamber sequential pacing device deployed into a heart, as shown on fluoroscopic imaging, according to the invention.
  • FIGURE 22 is an illustration of one embodiment of the transvenous dual-chamber sequential pacing device deployed into a heart, as shown on fluoroscopic imaging, according to the invention.
  • FIGURE 23 is an illustration of one embodiment of the transvenous dual-chamber sequential pacing device deployed into a heart, as shown in a cut-away view into the heart, according to the invention.
  • FIGURE 24 is an illustration of one embodiment of the transvenous dual-chamber sequential pacing device deployed into a heart, with ventricle leads deployed from a movable inner sheath into the ventricle, according to the invention.
  • FIGURE 25 is an illustration of one embodiment of the transvenous dual-chamber sequential pacing device deployed into a heart, with atrium leads being deployed from a movable inner sheath into the atrium, while ventricle leads have already been deployed into the ventricle, according to the invention.
  • FIGURE 26 is an illustration showing how the device can sense abnormal heart rhythm using the transvenous dual-chamber sequential pacing device deployed into a heart, according to the invention.
  • FIGURE 27 is an illustration showing how the device can provide electrical stimulation to the atrium using the transvenous dual-chamber sequential pacing device deployed into a heart, according to the invention.
  • FIGURE 28 is an illustration showing how the device can provide electrical stimulation to the ventricle using the transvenous dual-chamber sequential pacing device deployed into a heart, according to the invention.
  • FIGURE 29 is an illustration showing how the device can sense the corrected normal heart rhythm using the transvenous dual-chamber sequential pacing device deployed into a heart, according to the invention.
  • FIGURE 30 is an illustration showing how the device is removed after being deployed into a heart, according to the invention.
  • FIGURE 31 is an illustration of a ventricle only embodiment of the invention.
  • FIGURE 32 is an illustration of leads having a shape and constructed of materials to reduce endothelial injury and maximize energy transfer and signal transduction.
  • FIGURE 33 is an illustration of leads having a shape and constructed of materials to reduce endothelial injury and maximize energy transfer and signal transduction.
  • FIGURE 34 is an illustration of the outer sheath delivered to a location just above the junction of the superior vena cava and the right atrium (“the SVC-RA junction”), with the inner sheaths delivering their leads to the right atrium and the right ventricle, respectively.
  • FIGURE 35 is a flowchart showing a sequential process for deploying and optionally calibrating the leads.
  • Disclosed embodiments are directed to a self-positioning, quick-deployment low profile transvenous electrode system for sequentially pacing both the atrium and ventricle of the heart in the “dual chamber” mode, comprising a plurality of insulated electrical wires bundled together to form at least two in-line sets of leads is disclosed.
  • the invention provides an emergency pacemaker that will pace and sense both atrial and ventricular chambers and provide “dual chamber” control of the heart using a lead that can be safely and easily inserted into the heart in an emergency situation.
  • “Dual chamber” pacing refers to continuous monitoring of the spontaneous activity of the heart both in the atria and in the ventricles, interpreting the detected events according to certain accepted algorithms and providing stimuli to the chambers as needed to maintain a physiologically appropriate rhythm.
  • the device can be deployed with and without fluoroscopic guidance.
  • a self-positioning feature allows the device to be used without the extensive training and specialist experience that has been historically required for pacing devices.
  • the device comprises three (3) ventricular leads and four (4) atrial leads, made from shape memory material. Two of the three ventricular leads are bent at 90 degrees from the central axial lead and are 180 degrees from each other.
  • the four atrial leads are bent at 90 degrees from the central axis (x-axis), and are each separated 90 degrees from the adjacent leads, in the y-axis plane.
  • both sets of leads are mounted and contained inside a slender e.g. 8Fr (1 mm), tubular, flexible elongated e.g. 35 cm retaining sheath that serves as a guide and delivery system during insertion and removal of the electrode system.
  • Each of the wires is surrounded individually by electrical insulation.
  • the bundle of insulated wires can be arranged in either a parallel or helical configuration. In order to conform to heart chambers of different sizes, the leads will be produced in different lengths and appropriate distances between the electrodes.
  • the electrode system is constructed by assembling a plurality of insulated superelastic electrically conductive wires.
  • the insulation material separates each of the wires from each other, but the wires are mounted in a bundle as a single cable-like structure.
  • the electrodes are connected to an external pacemaker.
  • the individual wires once inserted into the heart will make contact with either atrial or ventricular tissue.
  • the distal ends of the individual wires may include spherical electrode contacts that will make contact with atrial tissue or ventricular tissue.
  • each of the wires has memory and is preformed in a specific curvature but also is resilient enough to be contained in the sheath prior to being positioned within the heart chambers. Since both sets of leads for the ventricle and the atrium are contained inside a single slender flexible retaining sheath that is the guide and delivery system during insertion and removal of the electrode system, the ventricular electrode or electrodes which can be pacemaker sensors or stimulators are released first after the retaining sheath has been successfully inserted into the right ventricle. At this point, the sheath is retracted allowing the ventricle wire leads to escape from the sheath and because of each wire's pre-formed shape which has memory, spread out to individually contact the endocardial surfaces.
  • the leads expand outwardly, engaging the tissue and chamber wall of the ventricle. If a mechanical parallel wire configuration is chosen in the sheath, the wires can be released and make contact in the same plane. Otherwise, the wires can be staggered within the ventricular chamber. If a helical configuration of the wires is chosen in the sheath, the wires are staggered upon release to cover different points of a chamber wall. Ideal wires for this configuration are disclosed in U.S. Pat. No. 6,137,060 and U.S. Pat. No. 3,699,886. Continued retraction of the sheath will then allow the escape of the atrial wires and electrodes which also have memory and which, upon escape from the sheath, will proceed outwardly towards the atrial tissue for engagement.
  • the distal ends of the individual wires may have spherical conductive ball tips to provide high current density and sensitivity.
  • the sheath will have to be extended all the way forward initially such that it covers all the wires with the possible exception of the distal electrodes, which may protrude beyond the sheath during the introduction of the sheath with the conducting leads into the heart.
  • the path of the sheath with the leads during insertion is into the subclavian or jugular vein past the atrium and into the ventricle.
  • each lead wire is made of stainless steel, or a superelastic or memory shape retention material such as NitinolTM, and as the sheath is slowly pulled back the lead wires are released.
  • Each lead wire will be preshaped with the proper orientation so that as the medical personnel, e.g. cardiac interventionalists, emergency medical technicians, surgical staff, outpatient staff, etc., pulls the sheath back, the wire fans outwardly until the lead wire tips rest against the interior wall of each chamber, thus making electrical contact.
  • the memory in the lead wire will hold it in place within the chamber.
  • BIOCOMPATIBLE MATERIALS Any of the devices and/or components thereof, including the lead wires, may be fabricated from any suitable biocompatible material or combination of materials.
  • an outer chassis, and/or components thereof may be fabricated from biocompatible materials, metals, metal alloys, polymer coated metals, and/or the like.
  • Suitable biocompatible materials, metals and/or metal alloys can include polymers, co-polymers, ceramics, glasses, aluminum, aluminum alloys, stainless steel (e.g., 316 L stainless steel), cobalt chromium (Co-Cr) alloys, cobalt chromium molybdenum (Co-Cr-Mo) alloy, cobalt chromium nickel molybdenum (Co-Cr-Ni-Mo) alloy, nickeltitanium alloys (e.g., Nitinol®), and/or the like.
  • stainless steel e.g., 316 L stainless steel
  • Co-Cr cobalt chromium
  • Co-Cr-Mo cobalt chromium molybdenum
  • Co-Cr-Ni-Mo cobalt chromium nickel molybdenum
  • nickeltitanium alloys e.g., Nitinol®
  • any of the chassis or components may be covered with a suitable polymer coating, and can include parylene-based polymers, parylene N, parylene C, parylene D, polytetrafluoroethylene (PTFE), ethylenetetrafluoroethylene (ETFE), polyimide, natural or synthetic rubber, polyethylene vinyl acetate (PEVA), poly-butyl methacrylate (PBMA), translate Styrene Isoprene Butadiene (SIBS) copolymer, polylactic acid, polyester, polylactide, D-lactic polylactic acid (DLPLA), polylactic-co- glycolic acid (PLGA), and/or the like.
  • PTFE polytetrafluoroethylene
  • ETFE ethylenetetrafluoroethylene
  • PEVA polyethylene vinyl acetate
  • PBMA poly-butyl methacrylate
  • SIBS translate Styrene Isoprene Butadiene copolymer
  • polylactic acid polyester, polylactide, D-lactic poly
  • any of the lead wires may also be fabricated from any suitable biocompatible material or combination of materials selected from solid or braided metal wire, wire with a first metal core (solid or braided) and a second metal outer shell layer (solid or braided), and combinations thereof.
  • a first metal core solid or braided
  • a second metal outer shell layer solid or braided
  • the insulation material used to insulate each individual wire will be of the type used in the production of existing pacing leads.
  • the sheath material used will be a thermoplastic elastomer similar to those used in the manufacture of catheters and for added strength it can be braided.
  • the electrode system in accordance with this invention may be designed primarily for emergency temporary use such that the leads described have passive fixation.
  • the present invention can be utilized as part of a permanently implanted pacemaker system such that the electrode would become embedded in the heart tissue or actively attached to the endocardium by one of many means available for active fixation.
  • Some biocompatible synthetic material(s) can include, for example, polyesters, polyurethanes, polytetrafluoroethylene (PTFE) (e.g., Teflon), and/or the like.
  • synthetic polymer materials such as parylene-based materials, expanded PTFE or polyester may optionally be used.
  • suitable materials may optionally include elastomers, thermoplastics, polyurethanes, thermoplastic polycarbonate urethane, polyether urethane, segmented polyether urethane, silicone polyether urethane, polyetheretherketone (PEEK), silicone-polycarbonate urethane, polypropylene, polyethylene, low-density polyethylene (LDPE), high-density polyethylene (HDPE), ultra-high density polyethylene (LIHDPE), polyolefins, polyethylene-glycols, polyethersulphones, polysulphones, polyvinylpyrrolidones, polyvinylchlorides, other fluoropolymers, polyesters, polyethylene-terephthalate (PET) (e.g., Dacron), Poly-L- lactic acids (PL
  • Barium Sulfate Barium sulfate (BaSO4) is a radiopaque material widely compounded in medical formulations and a common filler used with medical-grade polymers. It is an inexpensive material, costing approximately $2/lb; and its white color can be changed with the addition of colorants. With a specific gravity of 4.5, barium sulfate is generally used at loadings of 20 to 40% by weight. While a 20% barium sulfate compound is typical for general-purpose medical device applications, some practitioners prefer a higher degree of radiopacity than can be provided by that loading. With striped tubing, for example, a 40% compound is standard.
  • a loading of 20% barium sulfate by weight is equivalent to about 5.8% by volume; 40% by weight equals 14% by volume.
  • compounds begin to show losses of the base polymer's tensile strength and other mechanical properties. It is therefore best to formulate radiopacifiers at the minimum level for each application; excessive use of these fillers is not recommended.
  • Bismuth Considerably more expensive than barium at $20 to $30/lb (depending on the chemical salt selected), bismuth compounds are also twice as dense.
  • Bismuth trioxide (Bi2O3), which is yellow in color, has a specific gravity of 8.9; bismuth subcarbonate (Bi2O2CO3) has a specific gravity of 8.0; and bismuth oxychloride (BiOCI) has a specific gravity of 7.7. Because of the density, a 40% bismuth compound contains only about half the volume ratio as a 40% barium sulfate compound. Since bismuth produces a brighter, sharper, higher-contrast image on an x-ray film or fluoroscope than does barium, it is commonly used whenever a high level of radiopacity is required.
  • a 60% bismuth compound can maintain the same base polymer mechanical properties as a 40% barium sulfate compound.
  • a 20% bismuth loading by weight equals 3% by volume; a 40% loading by weight equals 7.6% by volume.
  • Bismuth is sensitive to compounding and must be treated gently, with low-shear mixing recommended for optimum results.
  • Bismuth provides high levels of radiopacity.
  • Tungsten A fine metal powder with a specific gravity of 19.35, tungsten (W) is more than twice as dense as bismuth and can provide a high attenuation coefficient at a cost of approximately $20/lb.
  • a loading of 60% tungsten has approximately the same volume ratio as a 40% bismuth compound.
  • Devices can be made highly radiopaque with relatively low loadings of tungsten, enabling good mechanical properties to be maintained. Because of its density, tungsten is typically selected as a filler for very- thin-walled devices. A 50% tungsten loading by weight equals only 5.4% by volume; an 80% loading by weight represents 18.5% by volume. Tungsten is black in color, which cannot be changed with colorants. It is abrasive and can cause accelerated wear in extruders and other processing equipment. Devices filled with high loadings of tungsten will exhibit surface roughness. Because the material invites oxidation in the presence of oxygen and heat and is highly flammable, care should be taken while drying it.
  • barium sulfate mixes better than do tungsten or bismuth compounds.
  • COMPOUNDING CONSIDERATIONS Newer x-ray machines generally operate at higher energy levels than older ones — typically at 80 to 125 kVp as compared with 60 to 80 kVp for older machines. Higher energy radiation increases the transmission of photons and can require higher levels of radiopacity to provide the desired attenuation. Therefore, devices produced with barium sulfate compounds might not appear as bright on newer machines, for which bismuth compounds would be a better choice of radiopaque filler. Blending these materials, however, can often be the best solution, especially for multipurpose formulations used over a broad range of energy levels.
  • Compounding radiopaque materials includes factoring in the degree of attenuation of the device, the tensile strength, elongation, and other mechanical properties of the polymers. Fillers, antioxidants, stabilizers, and colorants may also be included with metallic fillers. DELIVERY The present invention can be used in emergency rooms, after open heart surgery, during or after minimally invasive heart surgery or implant procedures such as valve repair or replacement, in intensive care units, at the bedsides, cardiac catheterization labs, ambulances, battle fields and other emergency settings where patients with heart block or other life threatening arrhythmias may be found.
  • the term “quick” or “quickly” refers to the aspect of the invention that the electrode system can be deployed in a short amount of time.
  • the electrode system can be deployed within a patient in approximately 1 minute.
  • the electrode system can be deployed within a patient in approximately 1-5 minutes.
  • the electrode system can be deployed within a patient in approximately 1-15 minutes.
  • the electrode system can be deployed within a patient in approximately 1-20 minutes.
  • the electrode system can be deployed within a patient in approximately 1-25 minutes.
  • the electrode system can be deployed within a patient in less than 25 minutes.
  • the electrode system can be deployed within a patient in less than 15 minutes.
  • the electrode system can be deployed within a patient in less than 5 minutes. In another preferred embodiment, the electrode system can be deployed within a patient in less than 3 minutes.
  • INDEPENDENT CLAIMS in a preferred embodiment, the invention provides an electrode system connectable to a pacemaker for sequentially pacing both the atrium and ventricle of a human heart comprising: a plurality of insulated electrical leads comprising a first set of ventricle leads and a second set of atrium leads, each said lead having an insulated wire and an atraumatic tip, said atraumatic tip comprising a domed head connected to a cylindrical sidewall, said cylindrical sidewall having a sloped proximal edge connected to a tapered coupling, said tapered coupling forming a smooth transition to an outer diameter of the insulated wire, a ventricular sheath disposed over said first set of ventricle leads, the ventricular sheath being retractable from the ventricle leads to deploy the ventricle leads in the ventricle, each of the ventricle leads having
  • the invention provides a method for quickly deploying a cardiac pacing device to a heart in a patient, comprising: (i) Providing the system herein; (ii) Accessing a jugular vein in the patient and advancing the catheter sheath under ultrasound or other non-fluoroscopic imaging modality to a right ventricle of the heart of the patient; (iii) Withdrawing the outer catheter sheath to a first position to deploy the first set of three ventricle leads; (iv) Withdrawing the outer catheter sheath to a second position to deploy the second set of four atrium leads; (v) Performing a diagnostic test using the first set of three ventricle leads and the second set of four atrium leads to identify patient cardiac patterns and to validate the operation of the system; (vi) Performing a cardiac pacing routine appropriate as a treatment for the patient cardiac pattern using the system.
  • the invention provides a self-positioning, quick-deployment low profile transvenous electrode system for pacing of a heart with a pacemaker, comprising: a pair of insulated electrical wires to form a first ventricle lead and a second ventricle lead, the first and the second ventricle leads disposed within an outer steerable catheter sheath, said outer steerable catheter sheath being removable from said first and said second ventricle leads when inserted into the heart for deploying the first ventricle lead and the second ventricle lead to the ventricle, said outer steerable catheter sheath being entirely removed from the ventricle when the transvenous electrode system is engaged, each of the first and the second ventricle leads have a proximal body portion, a distal end portion, and a tip portion, the proximal body portion made from a radiopaque polymer-covered copper wire, the distal end portion made from shape memory material, the shape memory material selected from stainless steel, spring steel, cobalt-chro
  • any of the embodiments herein may include wherein the first set comprises three ventricle leads and the second set comprises four atrium leads.
  • the electrode system is configured for withdrawal from the heart so that the atrium leads are returnable to the atrial sheath and the ventricle leads are returnable to the ventricular sheath at a location above the SVC-RA junction.
  • the atraumatic tip includes a metal portion comprised of stainless steel, nickel-titanium alloy, gold, platinum, or iridium.
  • any of the embodiments herein may include wherein the atrium leads are the same length or different staggered lengths, having a pre-set curved shape, and extend about 2.00 inches from a central axis of the atrial sheath.
  • the ventricle leads comprise a straight distal ventricle lead and two pre-set curved shape ventricle leads, the ventricle leads are the same length or different staggered lengths, the straight distal ventricle lead extending along a central axis of the atrial sheath, and the two pre-set curved shape ventricle leads extend about 1 .50 inches from the central axis of the atrial sheath.
  • any of the embodiments herein may include wherein when deployed in the ventricle, one of said ventricle leads is a distal ventricle lead extending along a central axis of the atrial sheath, and two ventricle leads are memory shape-set at 90 degrees to the central axis and are offset 180 degrees from each other in a plane perpendicular to the distal ventricle lead.
  • Any of the embodiments herein may include wherein when the atrium leads are deployed in the atrium, the atrium leads are memory shape-set at 90 degrees to a central axis of the atrial sheath and offset 90 degrees from each other in a plane perpendicular to the central axis.
  • Any of the embodiments herein may include where the atrium leads and the ventricular leads have different lengths.
  • any of the embodiments herein may include having a steerable delivery catheter with a female Luer connector, a side-port Tuohy Borst access connector, a deployment stopper, a terminal connection connected to the electrical leads, and an extension hub, the atrial sheath disposed within the steerable delivery catheter, the ventricular sheath disposed within the atrial sheath.
  • the steerable delivery catheter has an inner PTFE liner, a Tie layer, a braid, an outer jacket, and a heat shrink fusing sleeve located near a distal tip.
  • any of the embodiments herein may include wherein the steerable delivery catheter has an outer diameter (OD) of 0.104+-.003 inches, an inner diameter (ID) of .090+-.002 inches, and a working length of 12.00+-.30 inches.
  • OD outer diameter
  • ID inner diameter
  • ID working length
  • the female Luer connector has a connector orientation that is keyed to a leads orientation of the electrical leads, wherein the connector orientation informs an operator of the leads orientation.
  • the steerable delivery catheter has a dead-stop marker to indicate a maximum safe distance of insertion of the electrical leads.
  • any of the embodiments herein may include wherein the ventricular sheath comprises a stoplight extrusion having three (3) conduits (lumens), the inner diameter of the three conduits (lumens) configured to deliver the ventricular leads.
  • the atrial sheath comprises a 4- in-1 extrusion having a central axial conduit (lumen)and four perimeter conduits (lumens), the inner diameter of the central axial conduit (lumen)configured to deliver the ventricular sheath, and the inner diameter of the four perimeter conduits (lumens) configured to deliver the atrial leads.
  • the atrial sheath and the ventricular sheath have radio-opaque distance markers.
  • any of the embodiments herein may include wherein the electrical leads are monopolar, either positive or negative polarity. Any of the embodiments herein may include wherein when connected to a pacemaker, the distal ventricle lead and a second ventricle lead have a signal of a first polarity, and a third ventricle lead has a signal of an opposite polarity. Any of the embodiments herein may include wherein when connected to a pacemaker, two of the atrium leads have a signal of a first polarity and two of the atrium leads have a signal of an opposite polarity.
  • CROSS-TALK Any of the embodiments herein may include wherein the insulated wire of each of the atrium leads and the ventricle leads are radio-opaque, comprised of PTFE or PTE, and prevent cross-talk.
  • any of the embodiments herein may include wherein each of said electrical leads has a proximal portion made from wire with a radio-opaque material and a distal portion made from a shape memory material. Any of the embodiments herein may include wherein each of said atraumatic tips has a radio-opaque material.
  • any of the embodiments herein may include wherein the ventricular sheath and atrial sheath are each made from a polymer that is doped in at least one segment with a radiopaque material to form a radiopaque polymer sheath, each of the ventricle and atrium leads have a proximal body portion, a distal end portion, and the atraumatic tip, the proximal body portion made from a radiopaque polymer-covered copper wire, the distal end portion made from shape memory material, the shape memory material selected from stainless steel, spring steel, cobalt-chromium alloy, nickeltitanium alloy, and mixtures thereof, the atraumatic tip made from a pulse transmitting material and a radiopaque material, the radiopaque material selected from a barium-containing compound, a bismuth-containing compound, a steel compound, a tungsten-containing compound, and mixtures thereof, two of the three ventricle leads are memory shape-set at a 90 degree angle in an expanded configuration, and the
  • any of the embodiments herein may include wherein the atrium leads and the ventricle leads each connect to lead terminals that extend from a cable junction housing to a pacemaker, wherein the pacemaker comprises computer program instructions readable by a processor to provides functions selected from the group consisting of: a diagnostic function, a sensor operation, a stimulation signal, a program for an individual lead for sensing, a program to reduce over-sensing of the ventricular leads by T-waves or other noise or attenuating or interfering signals, a program to reduce over-sensing of the atrium leads by the R-wave, a program to minimize cross-talk, and a program to adjust sensing and stimulation on a lead-by- lead basis.
  • the pacemaker comprises computer program instructions readable by a processor to provides functions selected from the group consisting of: a diagnostic function, a sensor operation, a stimulation signal, a program for an individual lead for sensing, a program to reduce over-sensing of the ventricular leads by T-waves or other
  • any of the embodiments herein may include wherein the atrium leads are memory shape-set to sense and stimulate an atrial endothelium and the ventricle leads are memory shape-set to sense and stimulate an ventricular endothelium.
  • each of said ventricle leads is connected to a ventricular sensor or stimulator in a pacemaker and each of said atrium leads is connected to an atrium sensor or stimulator in said pacemaker.
  • the electrical leads are connected to a pacemaker that includes two sequential pulse generators to provide sensing and stimuli for a ventricle and for an atrium for sequentially pacing both the atrium and ventricle of a heart in the “dual chamber” mode.
  • pacemaker includes computer program instructions executable by a processor for performing digital signal processing for the ventricle leads and the atrium leads, wherein the digital signal processing is selected from the group consisting of: multiple input, multiple output (MIMO), single input multiple output (SIMO), single input single output (SISO), and multiple input single output (MISO).
  • MIMO multiple input, multiple output
  • SIMO single input multiple output
  • SISO single input single output
  • MISO multiple input single output
  • any of the embodiments herein may include wherein the computer program instructions executable by a processor provides one or more functions selected from: decreasing sensitivity of certain leads and increasing sensitivity of other leads during a depolarization cycle (PQRST) allows the invention to increase SNR in the sensing function, decreasing or increasing stimulatory signals to one or more leads allows the invention to more accurately provide stimulation to cardiac tissue to provide a level of granularity to the stimulation function, programming leads so that sensing leads are not required to share the function of a shocking/stimulation leads, and bypassing damaged or degraded leads to allow continued functioning without requiring the entire device to be removed from a patient, this increasing the longevity of implanted devices using the inventive technology.
  • PQRST depolarization cycle
  • any of the dual chamber embodiments herein may include wherein the pacemaker includes two sequential pulse generators that can provide sensing and stimuli for a ventricle and an atrium for sequentially pacing both the atrium and ventricle of a heart in the “dual chamber” mode.
  • Any of the embodiments of the present invention may include 4 atrial, and 3 ventricular wires in a configuration where the atrial are 90 degrees from each about a Y-axis, and where the ventricular are in a planar configuration that is perpendicular to the central X-axis.
  • Any of the embodiments of the present invention may include wherein the atrial leads and ventricle leads have uninsulated wire in certain locations.
  • any of the embodiments of the present invention may include wherein the copper body portion is braided or bonded to the distal end portion, where the distal end portion is steel or NiTi alloy. Any of the embodiments of the present invention may include wherein the shapesetting of the atraumatic tip is performed at the same time as the shape-setting of the wire portion of the leads. Any of the embodiments of the present invention may include wherein the shapesetting is performed faster by changing the wire cross section. Any of the embodiments of the present invention may include wherein the atraumatic tip is a composite of a shape memory material and a radiopaque material. Any of the embodiments of the present invention may include wherein the radiopaque materials are Tungsten, Barium, and/or Bismuth compounds.
  • Bismuth provides a brighter luminescence under Xray.
  • Bismuth compounds include Bi2O3, Bi2O2CO3, and BiOCI.
  • Barium sulfate provides excellent compounding with polymer coatings, such as polyimides.
  • Barium radiopaque polymers may be used for the catheter sheath/jacket, eyelet, as an RO band, and on other electrode portions, and sheath portions. Any of the embodiments of the present invention may include wherein the polymer is polyimide, or where the polymer is silicone plus a lubricity agent, is made from PebaSlix 35D, is made from Pebax 72D, and the like.
  • any of the embodiments of the present invention may include wherein the sheath is configured to provide a 90 degree curve over a 2.5” diameter bend, and is also configured to provide a hockey-stick bend at a 45 degree angle +/- 5 degrees.
  • the lead wires are unipolar or bipolar.
  • the lead wires are solid wire, braided wire, coaxial with an inner conductor and outer insulator, and/or co-radial with two parallel helically coiled wires.
  • any of the embodiments of the present invention may alternatively include wherein the lead wires are composite having a low-resistance inner metal such as stainless steel or silver, and a high-strength outer shell metal such as nickel-titanium alloy, titanium, stainless steel, and platinum alloy.
  • the polymer insulation is parylene, polytetrafluoroethylene (PTFE), ethylenetetrafluoroethylene (ETFE), polysiloxane, HP silicone, ETR silicone, poly(ether)urethane, and copolymer hybrid composites configured to have strength, lubricity, abrasion resistance, flexibility, and biostability for use as lead wire electrode insulation.
  • the lead wire tip may be configured with a textured surface, a mesh surface, a metal foam surface, a micro-perforated surface, or sintered metal wire mesh surface.
  • COMPUTER PROGRAMS in another preferred embodiment, the invention provides wherein the invention includes computer program instructions executable on a processor for performing one or more functions selected from: decreasing sensitivity of certain leads and increasing sensitivity of other leads during a depolarization cycle (PQRST) allows the invention to increase SNR in the sensing function, decreasing or increasing stimulatory signals to one or more leads allows the invention to more accurately provide stimulation to the atrial endothelium and the ventricular endothelium.
  • PQRST depolarization cycle
  • the sensing and stimulation may be directed to cardiac tissue to provide a level of granularity to the stimulation function, programming leads so that sensing leads are not required to share the function of a shocking/stimulation leads, and bypassing damaged or degraded leads to allow continued functioning without requiring the entire device to be removed from a patient, this increasing the longevity of implanted devices using the inventive technology.
  • the invention provides a method for quickly deploying a cardiac pacing device to a heart in a patient, comprising: (i) Providing the transvenous, dual-chamber dual-lumen system claimed and described herein; (ii) Accessing a jugular vein in the patient and advancing the catheter sheath under ultrasound or other non-fluoroscopic imaging modality to a right ventricle of the heart of the patient; (iii) Withdrawing the outer steerable catheter sheath to a first position to expose the first inner sheath and the second inner sheath; (iv) Withdrawing the first inner sheath to a second position to expose and actuate the ventricle leads to connect with the ventricle tissue; (iv) Withdrawing the second inner sheath to a third position to expose and actuate the atrium leads to connect with atrium tissue; (v) Performing a diagnostic test to identify the patient cardiac patterns and to validate the operation of the system; (vi) Performing a cardiac
  • the invention provides, wherein performing steps (i)-(vii) are performed in a time period no longer than 30 minutes. In another preferred embodiment, the invention provides, wherein performing steps (i)-(iv) are performed in a time period no longer than 3-5 minutes. In another preferred embodiment, the invention provides, wherein the system is deployed in a patient for a time period from 1 hour up to 7 days of use. In another preferred embodiment, the invention provides a transvenous electrode system for heart block use in an emergency situation that is low cost, safe and reliable for pacing both the atrium and ventricle chambers of the heart of a patient with a heart block.
  • the invention provides an emergency heart pacemaker that requires only a small incision to insert the lead that will provide dual chamber (sequential) pacing and sensing for the atrial and ventricles of the heart.
  • the invention provides emergency pacemaker that will avoid problems of single chamber ventricular pacing so that the present invention provides for atrial-ventricular synchrony.
  • the terms “comprises” and/or “comprising,” when used in this specification, specify the presence of stated features, integers (or fractions thereof), steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, integers (or fractions thereof), steps, operations, elements, components, and/or groups thereof.
  • the term “comprising” means “including, but not limited to.”
  • the term “and/or” includes any and all combinations of one or more of the associated listed items.
  • CARDIAC ELECTROPHYSIOLOGY The electrical conduction system of the heart uses Nodal cells and Purkinje cells to maintain synchronization of the atria and the ventricle.
  • the electrical current is first initiated in the SA node, the hearts natural pacemaker, located at the top of the right atrium.
  • the SA node is composed of nodal cells.
  • the SA node initiates firing at 60 to100 impulses/minute, the impulses causing electrical stimulation and subsequent contraction of the atria.
  • the sinus node Located at the upper end of the septum, the sinus node creates the synchronized neurally-mediated signal for cardiac pacing.
  • the AV node is also made up of nodal cells and coordinates these incoming electrical impulses. After a slight delay so the atria can contract and complete ventricular filling, the AV node relays the impulse to Purkinje cells in the ventricle, initially conducted through the Bundle of His which extends along the septum, and which is then divided into the right bundle branch to conduct impulses to the right ventricle and the left bundle branch to conduct impulses to the left ventricle, causing ventricular contraction.
  • the signal flow from the A-V node to the free wall of the left ventricle is rapid to insure the free wall and septum contract in synchrony.
  • a stimulating signal may flow to the free wall in about 70-90 milli-seconds.
  • this timing may be significantly delayed (to 150 milli-seconds or more) resulting in asynchronous contraction.
  • the conduction path through the Purkinje fibers may be blocked.
  • the location of the block may be highly localized (as in the case of so-called “left bundle branch block” or LBBB) or may include an enlarged area of dysfunctional tissue (which can result from infarction).
  • LBBB left bundle branch block
  • all or a portion of the free wall of the left ventricle is flaccid while the septum is contracting.
  • the contraction force of the free wall is weakened.
  • CHF patients can be treated with cardiac pacing of the left ventricle.
  • FIGURE 1 is an illustration of one embodiment of an optimized lead having a shape and constructed of materials to reduce endothelial injury and maximize energy transfer and signal transduction, according to the invention.
  • Fig. 1 shows atraumatic tip 10 having domed head 11 , cylindrical sidewall 12, sloped proximal edge 13, tapered coupling 14, and insulated wire 15 mounted within aperture 16 (not visible).
  • FIGURE 2 is an illustration of one embodiment of an optimized lead having a shape and constructed of materials to reduce endothelial injury and maximize energy transfer and signal transduction, according to the invention.
  • Fig. 2 shows domed head 11 , cylindrical sidewall 12, tapered coupling 14, and insulated wire 15.
  • FIGURE 3 is an illustration of one embodiment of an optimized tip of a lead having a shape and constructed of materials to reduce endothelial injury and maximize energy transfer and signal transduction, according to the invention.
  • Fig. 3 shows domed head 11 , cylindrical sidewall 12, sloped proximal edge 13, and wire aperture 16.
  • FIGURE 4 is an illustration of one embodiment of the deployable intracardiac portion of the device, illustrating the distal lead with rounded capsule tip, the two ventricular leads with rounded capsule tips, the four atrial leads with rounded capsule tips, the retractable ventricular sheath, and the retractable atrial sheath, according to the invention.
  • Fig. 4 shows pre-set-curved shape atrium leads 41 , pre-set curved shape ventricle leads 42, straight distal ventricle lead 43, atrial sheath 44, and ventricular sheath 45.
  • FIGURE 5 is an illustration of one embodiment of the deployable intracardiac portion of the device in relation to the intravascular portion/distal extrusion, the proximal extrusion and the external terminal housing portion, illustrating the distal lead with rounded capsule tip, the two ventricular leads with rounded capsule tips, the four atrial leads with rounded capsule tips, the retractable ventricular sheath, the retractable atrial sheath, the proximal extrusion with distance markers and a stopper, the conical wire guide, and the external lead terminals, according to the invention.
  • Fig. 5 also shows steerable delivery catheter 51 with atrial sheath 52 and dead stop marker I preventer 53.
  • FIGURE 6 is an illustration of one embodiment of the conical wire guide in relation to the proximal extrusion and the intracardiac portion of the device, according to the invention.
  • Fig. 6 shows splitter housing unit 61 with atrial leads in channel 62, and ventricle leads in channel 63.
  • FIGURE 7 is an illustration of one embodiment of the external lead terminal housing in relation to the proximal extrusion and the intracardiac portion of the device, according to the invention.
  • Fig. 7 shows ventricle leads 70, atrial leads 71 , negative leads 72, positive leads 73, and electrical connectors 74 to connect the leads to the electrical connection.
  • FIGURE 8 is an illustration of one embodiment of the outer shaft with an extension hub, side-port Tuohy-Borst, female luer, and layered construction of the outer sheath, according to the invention.
  • Fig. 8 shows distal extrusion 801 , proximal extrusion 802, PTFE liner 803, Tie layer 804, braid wire 805, PET heat shrink 806, female Luer 807, side-port Touhy-Borst 808, and extension hub 809.
  • FIGURE 9 is a cross-sectional illustration of the stoplight extrusion 91 used for the ventricle leads. This figure shows the ventricular extrusion frame 91 having ventricle lead conduits (lumens) 92 for delivering the ventricle leads.
  • FIGURE 10 is a cross-sectional illustration of the 4+1 extrusion used for the four atrial leads and the inner ventricular sheath.
  • This figures shows the atrial extrusion frame 93 having perimeter atrial lead conduits (lumens) 94 for delivering the atrium leads, and the central axial conduit (lumen) 95 for delivering the ventricular sheath to the ventricle.
  • FIGURE 11 is a cross-sectional illustration of the stoplight extrusion used for the ventricle leads disposed within the 4+1 extrusion used for the four atrial leads. This figure shows the ventricular sheath disposed within the central axial conduit (lumen)of the atrial sheath.
  • FIGURE 12 is a schematic view of one embodiment of the device, illustrating the atrial lead wires, the ventricular lead wires, the retractable sheath, the combined hub and terminal connection, and steerable deployment mechanism, and the external lead terminals, according to the invention.
  • Figure 12 shows a distal central radio-opaque lead wire 101 is shown as one of a three-part set of ventricle lead wires.
  • Ventricle lead wires 102 and 103 are shown bent at 90 degrees away from the central axis of lead wire 101 , and are shown in a 180 degrees opposition position from each other - lead 102 is 180 degrees opposite lead wire 103 in the y- axial plane.
  • ventricle leads are formed from 0.010” stainless steel or Nitinol.
  • Lead wire 101 extends axially 6cm from a distal radio-opaque band.
  • Lead wires 102 and 103 bend away from the central lead and extend 4 cm away, each, from the central axis, respectively.
  • Atrium lead wires 104, 105, 106, 107 are bent 90 degrees extending away from the central axis, and are also bent 90 degrees from each other in the y-axis plane. Atrium leads extend 4cm away, each, from the central axis, respectively.
  • Steerable catheter sheath is comprised of a distal portion 109 that is 5cm in length and has a 0.010” pitch coil. In a preferred embodiment, the distal portion is made from PebaSlix 35D.
  • Steerable catheter sheath is also comprised of a proximal portion 113 that is 30cm in length and has a 0.020” pitch coil. In a preferred embodiment, the proximal portion is made from Pebax 72D.
  • the sheath is configured to provide a 90 degree curve over a 2.5” diameter bend, and is also configured to provide a hockey-stick bend at a 45 degree angle +/- 5 degrees.
  • Sheath has OS markers 110, 111 , 112 located every 10cm along its length from the distal tip 108.
  • sheath has a glued hub 114, a Touhy-Borst access connector with a side port 115.
  • Actuator dial 116 is located at the proximal end of the sheath and allows the sheath to be shaped and controlled.
  • Red deployment stop 117 connects the last 20cm 118 of the sheath to the cable junction housing 119.
  • Atrium lead terminals 120, 121 and ventricle lead terminals 122, 123 allow the device to be connected to and operated from an external unit such as a ICD, pacer, diagnostic, or other unit that can provide sensor operation, stimulation signal, programming for individual leads to improve sensing, avoid over-sensing of the ventricular lead by T-waves or other noise or attenuating or interfering signals, avoid over-sensing of the atrium leads by the R-wave, avoid cross-talk, or customize sensing and stimulation on a lead-by-lead basis. Also contemplated as within the scope of the invention is the use digital signal processing in conjunction with the use of multiple leads.
  • MIMO Multiple input, multiple output
  • SIMO single input multiple output
  • SISO single input single output
  • MISO multiple input single output
  • PQRST depolarization cycle
  • SIMO single input multiple output
  • SISO single input single output
  • MISO multiple input single output
  • decreasing sensitivity of certain leads and increasing sensitivity of other leads during a depolarization cycle (PQRST) allows the invention to increase SNR in the sensing function.
  • decreasing or increasing stimulatory signals to one or more leads allows the invention to more accurately provide stimulation to the atrial endothelium and the ventricular endothelium, which may optionally include other cardiac tissue to provide a level of granularity to the stimulation function not previously available to practitioners.
  • the availability of multiple, programmable leads means that sensing leads are not required to share the function of a shocking/stimulation leads. Further, damaged or degraded leads can be bypassed allowing continued functioning without requiring the entire device to be removed from a patient, this increasing the longevity of implanted devices using the inventive technology.
  • the device may be programmable to achieve either conventional bipolar or unipolar stimulation or to achieve the stimulation of the present invention through an external programmer or controlled automatically by the device. The selection can be based on user preference or be driven by physiological factors such as widths of the patient's QRS complex or the conduction interval between the stimulus to a far away region in the heart.
  • switching between the pacing of the present invention and conventional pacing can also be determined by the percentage of pacing with a preference for a higher percentage with the pacing of the present invention. Further, the switching from the conventional pacing to the present invention pacing can be used when there exists an exit block or the pacing electrode is located in infracted myocardium when conventional pacing can not effect the depolarization of the myocardium at the high output level.
  • the automatic determination can be effected through the deployment of any automatic capture detection technology that exists in the prior art.
  • wireless network enabled switching function for therapy optimization can also be implemented with the present invention. In such case, certain patient physiologic data are gathered by the implantable device and sent to a remote server/monitor through a wireless communication network.
  • FIGURE 13 is a schematic view another embodiment of the device, illustrating the atrial leads 104, 105, 106, 107, the ventricular leads 101 , 102, 103, the retractable sheath 109, 113, the hub 114, the independent terminal connection 119, and steerable deployment mechanism 116, and the external lead terminals 120, 121 , 122, 123, according to the invention.
  • This figure also shows a 20cm segment 118 from the deployment stop 117 and the terminal connection 119.
  • FIGURE 14 is a schematic of the two-inner sheath embodiment illustrating the outer steerable catheter sheath 301 housing the two inner sheaths 302, 303, with one inner sheath 303 having the ventricle leads and the other inner sheath 302 having the atrium leads, according to the invention.
  • Eyelet tip 305 is constructed with radiopaque material and configured/shaped, e.g. as a loop, to have a surface area larger than the point cross-section of a wire lead. In a preferred embodiment, the eyelet tip is 0.2-1 .0mm in area. Copper wire body portion 306 of the wire lead runs the length of the catheter from the pacemaker up to the distal shape memory portion 307.
  • Shape memory portion 307 is attached to the copper wire 306 by bond, braid, weld, etc.
  • FIGURE 15 is a schematic of the seven-inner sheath (multi-lumen) embodiment illustrating the outer steerable catheter sheath 401 housing the seven inner sheaths, with each inner sheath 404 having its own lead, and providing three (3) ventricle leads 403 and four (4) atrium leads 402, according to the invention.
  • Eyelet tip 405 is constructed with radiopaque material and configured/shaped, e.g. as a loop, to have a surface area larger than the point cross-section of a wire lead. In a preferred embodiment, the eyelet tip is 0.2-1 .0mm in area.
  • FIGURE 16 is a schematic of a cross-section of the seven-inner sheath (multi-lumen) embodiment 501 illustrating the outer steerable catheter sheath 501 housing the seven inner sheaths 502, 503, with each inner sheath its own lead, and providing three (3) ventricle leads and four (4) atrium leads, according to the invention.
  • an external pacemaker 614 is shown connected to a bundle of insulated wire electrical conductors wrapped in a sheath 612.
  • the pacemaker 614 as shown is connected to a bundle of seven insulated conductive wires, three wires 620, 622, 626 of which are disposed within the ventricle and four wires 630, 632, 634, 636 of which are disposed in the atrium 628.
  • the wires are bundled in a sheath 612 that was inserted into the ventricle and then pulled backward, exposing the three ventricle leads which are now contacting the walls of the ventricle due to the retained curved memory of each wire.
  • four additional electrodes 630, 632, 634, 636 are shown contacting atrial chamber 628 walls in accordance with the present invention.
  • the invention as disclosed is a low profile transvenous electrode system for sequentially pacing both the atrium and ventricle of the heart in a dual chamber mode.
  • a plurality of insulated electrical wires represented that are electrical conductors and that are wrapped in electrical insulators.
  • the wires are bundled together into two separate in-line sets of leads.
  • Each wire has memory and is resilient.
  • each wire is pre-formed in a particular curvature and length so that when disposed within a heart chamber, atrium or ventricle, the electrode end of the wire will engage the chamber wall for electrical pulse transfer.
  • the device comprises three (3) ventricular leads and four (4) atrial leads, made from shape memory material.
  • Two of the three ventricular leads are bent at 90 degrees from the central axial lead and are 180 degrees from each other.
  • the four atrial leads are bent at 90 degrees from the central axis (x-axis), and are each separated 90 degrees from the adjacent leads, in the y-axis plane.
  • Each of the wires in the ventricle could be of different lengths with different shapes so that when the sheath is removed, each wire expands out by memory to have sufficient resiliency in distance to contact the inner wall of the ventricle as shown with the electrode points flush against the ventricle wall. There is a certain amount of resiliency in each wire holding the wire against the wall during pacing in the position as shown.
  • the four wires used in the atrium are also pre-formed in curvature and length so that when the sheath is removed, wires expand resil iently against the walls of the atrium as shown in the drawing with electrode points disposed at the end of each wire against the wall tissue. The resiliency in each wire will hold the electrodes against the wall of the atrium while pacing.
  • the external pacemaker 14 provides the electrical pulses for the sequential pacing.
  • the pacemaker 14 has two sequential pulse generators 16 and 18 which are connected to the proximal ends of the wires for providing the sequential pulses to both the ventricle through wires and to the atrium through wires.
  • the external pacemaker itself is conventional in operation.
  • PULSE GENERATOR The term “pulse generator” is intended to include pacemakers and cardia resynchronization therapies (CRT), all known in the art. It will be appreciated that the prior art contains numerous examples of cardiac leads for placement in a chamber of the heart, electrodes, attachment mechanisms, conductors and/or connector pins.
  • the pulse generator contains internal circuitry for creating electrical impulses which are applied to the electrodes after the lead is connected to the pulse generator.
  • such circuitry may include sensing and amplification circuitry so that electrodes may be used as sensing electrodes to sense and report on the patient's electrophysiology.
  • the lead may be introduced to the vasculature through a small incision and advanced through the vasculature and into the right atrium RA and right ventricle to the position. Such advancement typically occurs in an electrophysiology lab where the advancement of the lead can be visualized through fluoroscopy.
  • the pulse generator may contain a battery as a power supply.
  • the pulse generator circuitry controls the parameters of the signals coupled to the electrodes. These parameters can include pulse amplitude, timing, pulse duration by way of example.
  • the internal circuitry further includes circuit logic permitting reprogramming of the pulse generator to permit a physician to alter pacing parameters to suit the need of a particular patient. Such programming can be affected by inputting programming instructions to the pulse generator via wireless transmission from an external programmer.
  • the electrode is connected by the circuitry to an electrical ground.
  • the pulse generator may be external and coupled to the electrodes by percutaneous leads or wireless transmission.
  • ELECTRODE LEADS The leads which are the wire conductors and electrodes are manufactured in different lengths and curved resiliently as discussed above with approximate distances between the electrodes to create a configuration or pattern as shown. In a preferred embodiment, the leads are established inside the ventricle and established in the atrium.
  • the wires may have memory and with their pre-formed curvatures are resilient enough to be bundled in a small sheath prior to being mounted within the heart chambers. Both sets of wires may be contained inside a single, cylindrical, flexible retaining sheath that is the guide and delivery system during insertion and removal of the electrode system.
  • the ventricular electrodes may be pacemaker sensors or stimulators are released first after the retaining sheath has been successfully inserted into the right ventricle. The sheath may be retracted allowing the electrodes and wires to spread out and contact the endocardial surfaces. The wires expand outwardly as the sheath is removed engaging the tissue and chamber wall of the ventricle.
  • the wires can be released and make contact on the same plane within the ventricular chamber or they can be staggered.
  • the continued retraction of sheath may allow the escape of the atrial wires from the sheath which proceed toward the atrial tissue for engagement of the electrodes against the atrial wall.
  • sequential pacing can be initiated in the atrium and ventricle in a dual chamber mode providing an emergency pacemaker that will pace and sense both atrial and ventricular chambers and provide dual chamber control of the heart.
  • FIGURE 18 is a chart of an acute first in human study and is useful to support an embodiment of the present invention. This figure shows an example study of a sample of 10 patients, although not necessarily for any specific indication. This figure illustrates that the device is positioned and deployed in the right side chambers of the heart with fluoroscopy guidance and once vascular access, internal jugular or subclavian is obtained.
  • FIGURE 19 is an example of a chart of data in an embodiment of the invention from a procedure recording a non-limiting preferred embodiment. This figure shows by subject and lead, the impedance, the threshold, and the current, recorded. This shows safe delivery with and without fluoroscopic guidance, successful pacing, excellent contact and hold of the leads against the cardiac tissue, with no adverse events or significant adverse events at discharge.
  • FIGURES 20A, 20B, 20C is a sequence illustration of one embodiment.
  • FIG. 20A shows a device being introduced into the jugular vein of a patient using a guidewire 901 and introducer 902. Luer 903 is shown connecting near hub 904, with outer delivery catheter 905 accessing down the jugular vein.
  • FIG. 20B shows removal of the guidewire 901 .
  • FIG. 20C shows introduction of the transvenous dual-chamber sequential pacing device having steerable catheter sheath 906 into the deliver catheter 905.
  • FIGURE 21 is an illustration of one embodiment of the transvenous dual-chamber sequential pacing device deployed into a heart using steerable catheter 906, as shown on fluoroscopic imaging.
  • FIGURE 22 is an illustration of one embodiment of the transvenous dual-chamber sequential pacing device deployed into a heart using steerable catheter 906, as shown on fluoroscopic imaging.
  • FIGURE 23 is an illustration of one embodiment of the transvenous dual-chamber sequential pacing device deployed into a heart using a steerable catheter 906, as shown in a cut-away view into the heart.
  • FIGURE 24 is an illustration of one embodiment of the transvenous dual-chamber sequential pacing device deployed into a heart, with ventricle leads 907, 908, 909 deployed from a movable inner sheath into the ventricle.
  • FIGURE 25 is an illustration of one embodiment of the transvenous dual-chamber sequential pacing device deployed into a heart, with atrium leads 910, 911 , 912, 913 being deployed from a movable inner sheath into the atrium, while ventricle leads have already been deployed into the ventricle.
  • FIGURE 26 is an illustration showing how the device can sense abnormal heart rhythm using the transvenous dual-chamber sequential pacing device deployed into a heart.
  • FIGURE 27 is an illustration showing how the device can provide electrical stimulation to the atrium using the transvenous dual-chamber sequential pacing device deployed into a heart.
  • Fig. 27 shows atrium leads 910-911 -912-913 providing stimulation to the atrium.
  • FIGURE 28 is an illustration showing how the device can provide electrical stimulation to the ventricle using the transvenous dual-chamber sequential pacing device deployed into a heart.
  • Fig. 28 shows ventricle leads 907-908-909 providing stimulation to the ventricle.
  • FIGURE 29 is an illustration showing how the device can sense the corrected normal heart rhythm using the transvenous dual-chamber sequential pacing device deployed into a heart.
  • Fig. 29 shows atrium leads 910-911-912-913 again providing stimulation to the atrium.
  • FIGURE 30 is an illustration showing how the device is removed after being deployed into a heart.
  • the leads may be removed by simply pulling, in one embodiment.
  • the sheath(s) may be re-introduced to gather the leads prior to removal.
  • FIGURE 31 is an illustration of a ventricle only embodiment of the invention.
  • catheter 2001 having the unipolar leads 2002, 2003 disposed therein.
  • the leads 2002, 2003 are shown having optional radiopaque insulating covering 2004 in a non-limiting embodiment.
  • Conventional temporary pacemaker 2005 is attached to the leads by way of the brachial vein to provide dual ventricular leads in the right ventricle for pacing.
  • the catheter if 4 French in size, or 4/3 mm (1 ,33mm) in diameter.
  • Leads 2002, 2003 may include radiopaque eyelet tips, and may also include a proximal portion made of copper with a distal portion made from steel or nickel-titanium (NiTi) alloy, in a non-limiting embodiment as previously described.
  • FIGURE 32 is an illustration of leads having a shape and constructed of materials to reduce endothelial injury and maximize energy transfer and signal transduction. This figure shows the atrium leads and the ventricle leads having a blunt electrode tip 2105.
  • the blunt, non-damaging tip 2105 may include radio-opaque materials or coatings. Non-limiting materials may be selected from barium, bismuth, tungsten, steel, or other known RO materials.
  • outer sheath 2101 having the atrium inner sheath 2102 and the ventricle inner sheath 2103 disposed therein.
  • Atrium leads 2108 and ventricle leads 2109 are shown extending from their respective inner sheaths.
  • Optional radio-opaque markers 2104 may also be mounted at various locations to assist the endoscopic practitioner with visualizing the proper placement of the system.
  • the leads, 2108 and 2109 may include a copper wire body having an optional polymer coat, and may optionally have a distal section made from a different material, such as shape memory materials NiTi, spring steel, or stainless.
  • FIGURE 33 is an illustration of leads having a shape and constructed of materials to reduce endothelial injury and maximize energy transfer and signal transduction. This figure shows the atrium leads and the ventricle leads having different selected electrode tips 2205, 2215, and 2225.
  • the blunt, non-damaging tip 2205 may include radio-opaque materials or coatings. Non-limiting materials may be selected from barium, bismuth, tungsten, steel, or other known RO materials.
  • the bullet-shaped, non-damaging tip 2215 may also include radio-opaque materials or coatings.
  • Nonlimiting materials may be selected from barium, bismuth, tungsten, steel, or other known RO materials.
  • the loop-shaped, non-damaging tip 2225 in Figs. 14-15 may include radio-opaque materials or coatings.
  • Non-limiting materials may be selected from barium, bismuth, tungsten, steel, or other known RO materials.
  • a loop-shaped tip may be indicated when contacting extensively convoluted trabeculae carneae to provide a larger lead surface without perforating or damaging the heart tissue.
  • Fig. 32 also shows outer sheath 2201 having the atrium inner sheath 2202 and the ventricle inner sheath 2203 disposed therein.
  • Atrium leads 2208 and ventricle leads 2209 are shown extending from their respective inner sheaths.
  • Optional radioopaque markers 2204 may also be mounted at various locations to assist the endoscopic practitioner with visualizing the proper placement of the system.
  • the leads, 2208 and 2209 may include a copper wire body having an optional polymer coat 2010, and may optionally have a distal section 2212 made from a different material, such as shape memory materials NiTi, spring steel, or stainless.
  • a shape memory material at the distal end of the lead provides for shape-setting the end portion in order to specify the angle and shape of the lead, thus allowing the lead to make conductive contact with the correct, selected location inside the atrium and ventricle.
  • FIGURE 34 is an illustration of the outer sheath 2301 delivered to a location just above the junction of the superior vena cava and the right atrium (“the SVC-RA junction”), with the inner sheaths 2302, 2303 delivering their leads to the right atrium and the right ventricle, respectively.
  • This figure shows that the outer sheath may remain within the superior vena cava (SVC), above the junction with the right atrium (“the SVC-RAjunction”), while the inner sheaths deliver their leads to their respective chambers, the right atrium (RA) and the right ventricle (RV).
  • SVC superior vena cava
  • RA right atrium
  • RV right ventricle
  • FIGURE 35 is a flowchart showing a non-limiting preferred embodiment of the sequential process for deploying and calibrating the leads.
  • Step 1 Deploy the transvenous intracardiac pacing catheter to the right ventricle of a patient.
  • Step 2 Partially withdraw the outer sheath to a first position to expose the inner ventricular sheath.
  • Step 3 Partially withdraw the inner ventricular sheath to deploy the shape-set ventricular pacing leads.
  • Step 4 Calibrate the ventricle leads and withdraw and re-deploy the ventricle leads from the inner ventricular sheath as needed.
  • Step 5 Partially withdraw the outer sheath to a second position to expose the inner atrial sheath.
  • Step 6 Partially withdraw the inner atrial sheath to deploy the shape-set atrial pacing leads.
  • Step 7 Calibrate the atrial leads and withdraw and redeploy the atrial leads from the inner atrial sheath as needed. It is also within the scope of the invention to sequence the deployment wherein the outer sheath is not delivered all the way into the right ventricle, but is instead Step 1 : delivered only to the SVC. In this embodiment, Step 2: the inner ventricle sheath is then extended and deployed to the right ventricle. Then, after the inner ventricle sheath delivers the ventricle leads to the right ventricle, Step 3: the inner ventricle sheath may be withdrawn to expose and deploy the ventricle leads to their functional locations within the right ventricle.
  • Step 4 the inner atrium sheath being extended and deployed to the right atrium.
  • Step 5 the inner atrium sheath may be withdrawn to expose and deploy the atrium leads to their functional locations within the right atrium.
  • Step 3b and Step 5b has the operator calibrating the ventricular leads and atrial leads, and optionally, withdrawing and re-deploying the leads if the impedance or transmission is not in the desired range.

Landscapes

  • Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Electrotherapy Devices (AREA)

Abstract

Les modes de réalisation décrits dans la description concernent un système d'électrode transveineuse à faible encombrement, à déploiement rapide et à autopositionnement pour stimuler séquentiellement l'oreillette et le ventricule du cœur dans le mode « double chambre » ayant une pointe atraumatique comprenant une tête bombée reliée à une paroi latérale cylindrique, ladite paroi latérale cylindrique ayant un bord proximal incliné relié à un raccord conique, ledit raccord conique formant une transition douce avec un diamètre externe du fil isolé, et des procédés de déploiement de celui-ci.
PCT/IB2024/055376 2023-07-26 2024-06-02 Cathéter de stimulation intracardiaque transveineuse ayant des dérivations améliorées Pending WO2025022188A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18/358,961 2023-07-26
US18/358,961 US12151099B2 (en) 2021-01-20 2023-07-26 Transvenous intracardiac pacing catheter having improved leads

Publications (1)

Publication Number Publication Date
WO2025022188A1 true WO2025022188A1 (fr) 2025-01-30

Family

ID=94374106

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/055376 Pending WO2025022188A1 (fr) 2023-07-26 2024-06-02 Cathéter de stimulation intracardiaque transveineuse ayant des dérivations améliorées

Country Status (1)

Country Link
WO (1) WO2025022188A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120392278A (zh) * 2025-07-01 2025-08-01 南昌大学第二附属医院 一种具有凝、切功能的高频电刀

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275956A1 (en) * 2008-04-30 2009-11-05 Medtronic, Inc. Techniques for placing medical leads for electrical stimulation of nerve tissue
US20100168739A1 (en) * 2008-12-31 2010-07-01 Ardian, Inc. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US20220226642A1 (en) * 2021-01-20 2022-07-21 Swift Sync, Inc. Transvenous intracardiac pacing catheter
US20220409239A1 (en) * 2021-06-25 2022-12-29 Crossliner, Inc. Enhanced guide extension system for the efficient delivery of leads
US11577075B1 (en) * 2018-10-12 2023-02-14 Vincent A. Gaudiani Transcoronary sinus pacing of his bundle

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275956A1 (en) * 2008-04-30 2009-11-05 Medtronic, Inc. Techniques for placing medical leads for electrical stimulation of nerve tissue
US20100168739A1 (en) * 2008-12-31 2010-07-01 Ardian, Inc. Apparatus, systems, and methods for achieving intravascular, thermally-induced renal neuromodulation
US11577075B1 (en) * 2018-10-12 2023-02-14 Vincent A. Gaudiani Transcoronary sinus pacing of his bundle
US20220226642A1 (en) * 2021-01-20 2022-07-21 Swift Sync, Inc. Transvenous intracardiac pacing catheter
US20220409239A1 (en) * 2021-06-25 2022-12-29 Crossliner, Inc. Enhanced guide extension system for the efficient delivery of leads

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120392278A (zh) * 2025-07-01 2025-08-01 南昌大学第二附属医院 一种具有凝、切功能的高频电刀

Similar Documents

Publication Publication Date Title
US11980756B2 (en) Transvenous intracardiac pacing catheter
US12397152B2 (en) Systems and methods for implanting a medical device
US12090319B2 (en) Implantable medical devices and methods for making and delivering implantable medical devices
US11957900B2 (en) Transvenous intracardiac pacing catheter
US10537731B2 (en) Transvenous mediastinum access for the placement of cardiac pacing and defibrillation electrodes
US10980570B2 (en) Implantation of an active medical device using the internal thoracic vasculature
CN111556774B (zh) 用于血管部署的可植入医疗装置
US10786679B2 (en) Lead with integrated electrodes
CA2249993C (fr) Derivation d'acces au ventricule gauche pour stimulation en cas de defaillance cardiaque
US12151099B2 (en) Transvenous intracardiac pacing catheter having improved leads
WO2025022188A1 (fr) Cathéter de stimulation intracardiaque transveineuse ayant des dérivations améliorées
US20250367455A1 (en) Transvenous Intracardiac Pacing Catheter Having Improved Leads
US12440669B2 (en) Transvenous intracardiac pacing catheter
US20240181248A1 (en) Transvenous intracardiac pacing catheter
EP4563189A1 (fr) Biostimulateur ayant un cadre extensible

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24844941

Country of ref document: EP

Kind code of ref document: A1